-
AHCA Secretary Jason Weida told a state House panel he is “cautiously optimistic” the FDA will approve the plan, which the state has been pursuing since 2019.
-
Repeated recalls of eyedrops are drawing new attention to the limited powers U.S. regulators have to oversee medical products made overseas.
-
Central Florida has one of the highest yearly diagnosis averages of sickle cell disease in the country, but a recently approved gene-editing treatment might bring relief.
-
Colorado officials say they haven’t been able to stand up a program to import drugs from Canada because of drugmaker opposition — and the Biden administration’s inaction.
-
Cinnamon from a manufacturer in Ecuador is the “likely source” of high levels of lead found in recalled pouches of applesauce puree linked to illnesses in at least 34 children in 22 states.
-
U.S. health inspectors found a host of sanitation and manufacturing problems at an Indian plant that recently recalled eyedrops sold in the U.S.
-
The surgical drug is being prescribed as a psychedelic therapy for an array of unapproved uses, including depression and anxiety. Behind the trend are investors setting up for-profit clinics.
-
On this episode, a panel of experts delves into the forefront of health care, dissecting the latest advancements and trends.
-
If approved by health regulators, it would be the first therapy on the U.S. market based on CRISPR, a gene editing tool that won its inventors the Nobel Prize.
-
Probiotics, which supplement regular feeding and contain live organisms such as bacteria or yeast, can lead to invasive, potentially fatal infections or disease, the FDA said.